The U.S. Defense Secretary Pete Hegseth announced the initiative, which integrates hormone level monitoring into annual health evaluations and offers voluntary hormone replacement therapy to those diagnosed with deficiencies.
Establishing a ‘Decisively Dominant’ Baseline
The Pentagon’s new protocol takes effect immediately. According to Pentagon spokesman Sean Parnell, the mandatory screenings for service members 30 and older are designed to establish a “comprehensive baseline” for troop health. The objective is clear: ensure the military maintains a “healthy, capable, and decisively dominant fighting force.”
Personnel under 30 may opt into the testing, but are not required to undergo it. The Pentagon has not yet clarified if the screenings will extend to female service members or if the program will eventually include evaluations for other hormonal shifts, such as those associated with perimenopause.
Medical Necessity vs. Artificial Enhancement
Secretary Hegseth framed the move as a commitment to long-term health, arguing the initiative keeps soldiers “strong, resilient and capable” even beyond their active service. In a video announcement posted to X, Hegseth was explicit: the program is “not about artificial enhancement.” He noted that using testosterone for non-medical purposes, such as muscle building without a prescription, remains strictly prohibited.
Clinical experts, however, urge caution. Dr. Mohit Khera, a professor of urology at Baylor College of Medicine and who led an FDA expert panel on screening and testosterone utilisation in the military, told the BBC that while low testosterone affects muscle mass and energy, intervention must be symptom-driven. “You have to be careful not to just give someone testosterone unless they do have some kind of symptoms,” Khera said. He warned that replacement therapy carries risks, including theoretical cardiovascular concerns and potential infertility for those in their reproductive years.
A Policy Caught in the Culture War
The mandate arrives amid a broader administrative shift toward testosterone therapy. U.S. Health Secretary Robert F. Kennedy Jr. has advocated for reducing barriers to prescriptions to address fertility concerns. Simultaneously, the FDA has proposed loosening prescribing limits and removing specific safety and effectiveness language from testosterone replacement product labeling.
The reaction on Capitol Hill has been fractured. Democratic Senator Tammy Duckworth, an Iraq war veteran, urged the Defense Department to ensure these testing services are available to both men and women. Other legislators view the move through a different lens. Congresswoman Chrissy Houlahan, an Air Force veteran, dismissed the announcement as a “culture-war obsession” in a post on X.
Program Specifications
- Target Demographic: Active-duty and reserve personnel aged 30 and older.
- Requirement: Mandatory screening for testosterone deficiency during annual health check-ups.
- Intervention: Voluntary hormone replacement therapy for those with clinical deficiencies.